Penn Spinout EpiVario Announces Acquisition of Acetyl CoA Synthetase 2 (ACSS2) Inhibitor Portfolio from Metabomed LTD

Penn spinout EpiVario, a biotech company focusing on neuroepigenetics for addiction disorders, has acquired small molecule acetyl co-A synthetase-2 inhibitor (ACSS2i) portfolio from Illinois-based company Metabomed LTD through an asset purchase agreement. This acquisition equips EpiVario with novel and selective ACSS2i compounds, that could be beneficial for addiction disorder treatment.

Thomas Kim, EpiVario’s CEO, expressed enthusiasm, stating that this deal accelerates EpiVario’s development program for addiction disorders, including opioids, cocaine, alcohol addiction, and PTSD. Read more here.

Skip to content